Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

GSK an­nounced an­oth­er batch of pos­i­tive da­ta from its res­pi­ra­to­ry pro­gram with the in­ves­ti­ga­tion­al drug de­pemokimab, this time in pa­tients with chron­ic rhi­nos­i­nusi­tis with nasal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER